INBS Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
1.1M
+8.0%
1.1M
+18.3%
896.8K
-19.3%
1.1M
+31.7%
843.9K
Cost of Revenue
609.2K
+15.9%
525.4K
+20.2%
437.0K
-26.4%
593.5K
+16.8%
508.3K
Gross Profit
536.6K
+0.2%
535.4K
+16.5%
459.7K
-11.3%
518.3K
+54.4%
335.6K
Operating Expenses
4.5M
+29.4%
3.5M
+12.5%
3.1M
-12.0%
3.5M
+2.2%
3.4M
R&D
1.5M
+64.3%
894.0K
+71.2%
522.1K
+7.4%
486.2K
-16.5%
582.5K
SG&A
3.0M
+21.6%
2.5M
+5.2%
2.3M
-12.1%
2.7M
-2.3%
2.7M
Operating Income
-3968735
-34.7%
-2947101
-11.8%
-2635738
+12.1%
-2999593
+3.4%
-3106365
EBITDA
-3676127
-38.6%
-2651508
-16.2%
-2281224
+8.0%
-2479906
+14.1%
-2886303
Net Income
-3917427
-36.5%
-2869640
-6.8%
-2686613
+10.3%
-2994992
+3.5%
-3102616
EPS (Basic)
$-1.80
+36.2%
$-2.82
+19.4%
$-3.50
-84.2%
$-1.90
EPS (Diluted)
$-1.80
+36.2%
$-2.82
+19.4%
$-3.50
-84.2%
$-1.90
Shares (Diluted)
1.6M
+67.7%
950.8K
+11.2%
854.7K
-47.4%
1.6M
Intelligent Bio Solutions (INBS) — Financials